Table 3 |
||||
|
ORs and 95%CI of sarcoma by ICD-IX code1 and levels of exposure, both sexes |
||||
| Average exposure (fgr/m3) |
||||
|
|
||||
| ICD-IX code |
<4 Cases/Controls OR (95% CI) |
4–6 Cases/Controls OR (95% CI) |
≥ 6 Cases/Controls OR (95% CI) |
χ12 for trend |
|
|
||||
| ICD-IX 171 (Cases/Controls: 81/190) |
25/80 1* |
39/93 1.35 (0.73 – 2.48) |
17/17 3.27 (1.35 – 7.93) |
5.89 (p = 0.0152) |
| ICD-IX 173 (Cases/Controls: 17/43) |
5/12 1* |
10/20 0,04 (0.31 – 4.71) |
2/11 0.34 (0.03 – 3.43) |
0.51 (p = 0.4758) |
| ICD-IX 158 (Cases/Controls: 21/49) |
6/14 1* |
12/27 1.06 (0.33 – 3.43) |
3/8 0.8 (0.14 – 4.45) |
0.03 (p = 0.8625) |
| Visceral sites (Cases/Controls: 53/123) |
19/55 1* |
22/52 1.24 (0.60 – 2.55) |
12/16 2.45 (0.96 – 6.28) |
3.02 (p = 0.0823) |
|
|
||||
|
* Reference category 1ICD-IX 171: malignant neoplasm of connective and other soft tissue; ICD-IX 173: malignant neoplasm of skin (other than melanoma of skin, Kaposi's sarcoma and skin of genital organs); ICD-IX 158: malignant neoplasm of retroperitoneum and peritoneum. |
||||
|
Zambon et al. Environmental Health 2007 6:19 doi:10.1186/1476-069X-6-19 |
||||